Drug-coated Balloon Catheter Market Size & Growth Forecast 2027–2036, By Segments (Type, Product, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Drug-coated Balloon Catheter Market size was around USD 1.3 billion in 2026 and is slated to grow at a 7.89% CAGR from 2027 to 2036, attaining USD 2.78 billion by 2036. The industry revenue for 2027 is calculated at USD 1.39 billion.
Get more details on this report
Request Free Sample ReportDrug-coated Balloon Catheter Market Intelligence Snapshot
Regional Market Dynamics
- North America led the market in 2026 due to established interventional cardiology infrastructure, broad access to catheter-based procedures, experienced physicians, and widespread adoption of advanced vascular technologies.
- Asia Pacific is projected to grow at a 9.04% CAGR, supported by expanding endovascular expertise, greater access to minimally invasive vascular care, and increasing adoption of advanced catheter therapies.
Segment Momentum
- Paclitaxel accounted for 91.21% of the market in 2026 due to its established clinical use, physician familiarity, and broad commercial availability, supporting routine adoption in vascular interventions.
- Peripheral Vascular Disease is the fastest-growing product segment while holding a 69.73% share, driven by strong demand for minimally invasive vascular procedures and continued adoption in routine peripheral interventions.
Market Expansion Drivers
- Rising prevalence of cardiovascular and peripheral artery diseases increasing minimally invasive vascular procedures.
- Expanding clinical preference for implant-free revascularization boosting drug-coated balloon adoption.
- Integration of AI-enabled imaging guidance enhancing interventional cardiology treatment precision.
Leading Market Participants
- Major players in the drug-coated balloon catheter market include Boston Scientific Corporation (United States), Medtronic plc (Ireland), Abbott Laboratories (United States), B. Braun SE (Germany), Koninklijke Philips N.V. (Netherlands), MicroPort Scientific Corporation (China), Lepu Medical Technology (Beijing) Co., Ltd. (China), Meril Life Sciences Pvt. Ltd. (India), Cordis Corporation (United States), Concept Medical Inc. (India).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.3 billion
- 2027 Estimated Market Size: USD 1.39 billion.
- Projected Market Size: USD 2.78 billion by 2036
- Growth Forecast: 7.89% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Paclitaxel (Type) | Peripheral Vascular Disease (Product) | Hospital (End-use)
- Emerging Opportunity Segment: Sirolimus (Type) | Peripheral Vascular Disease (Product) | Ambulatory Surgical Centers (End-use)
Market Growth Drivers and Industry Trends
Rising prevalence of cardiovascular and peripheral artery diseases increasing minimally invasive vascular procedures
The rising burden of cardiovascular and peripheral artery diseases is increasing the need for less invasive vascular interventions, which will drive the drug-coated balloon catheter market growth as clinicians seek treatment options that can restore blood flow while limiting procedural trauma. Growing incidence of arterial narrowing and vascular obstruction is encouraging healthcare providers to adopt catheter-based approaches that can be performed with shorter recovery periods compared with more invasive surgical procedures. Drug-coated balloon technology combines mechanical vessel expansion with localized delivery of therapeutic agents, helping address restenosis risks associated with vascular interventions. Greater awareness of minimally invasive treatment pathways, improvements in catheter design, and expanding availability of interventional vascular procedures are supporting its use across peripheral and coronary applications.
Expanding clinical preference for implant-free revascularization boosting drug-coated balloon adoption
A growing preference for implant-free treatment approaches is strengthening demand, and the drug-coated balloon catheter market will benefit as interventional specialists increasingly consider revascularization strategies that avoid leaving a permanent device inside the vessel. Drug-coated balloons can deliver an antiproliferative drug directly to the treated vascular segment while eliminating the need for a permanent stent in suitable cases, which can be advantageous for patients requiring future vascular access or those with vessel characteristics that make implantation less desirable. Clinical efforts to reduce the complications associated with implanted devices, including thrombosis and challenges associated with repeat interventions, are encouraging physicians to evaluate balloon-based therapies for appropriate lesions. Continued clinical experience and improvements in drug delivery and balloon technology are further supporting physician familiarity with implant-free revascularization.
Integration of AI-enabled imaging guidance enhancing interventional cardiology treatment precision
Advances in artificial intelligence and image-guided intervention are creating new opportunities for more precise vascular procedures, with AI-enabled imaging capabilities helping propel the drug-coated balloon catheter market by supporting improved lesion assessment and procedural decision-making. AI-assisted systems can help clinicians interpret complex vascular images, identify areas of narrowing, assess lesion characteristics, and support more consistent navigation during catheter-based procedures. Greater integration of imaging data with interventional workflows can improve visualization of vessel anatomy and assist specialists in selecting appropriate treatment strategies and device positioning. As hospitals increasingly adopt digital technologies within interventional cardiology, the combination of advanced imaging, clinical decision support, and minimally invasive devices is strengthening the technological foundation for more precise vascular treatment.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of cardiovascular and peripheral artery diseases increasing minimally invasive vascular procedures | 2.10% | High | North America, Europe | High | Near Term |
| Expanding clinical preference for implant-free revascularization boosting drug-coated balloon adoption | 1.90% | Moderate | Asia Pacific, North America | High | Mid Term |
| Integration of AI-enabled imaging guidance enhancing interventional cardiology treatment precision | 1.50% | Moderate | Europe, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest position in the drug-coated balloon catheter market in 2026, supported by advanced cardiovascular care infrastructure, high adoption of minimally invasive interventions, and strong clinical capabilities. The region’s established healthcare systems facilitate the use of specialized catheter-based technologies for vascular disease management, while growing emphasis on less invasive treatment approaches supports demand for drug-coated balloon solutions. Continued healthcare investment and increasing focus on improving procedural outcomes further reinforce regional adoption.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, driven by expanding cardiovascular care infrastructure, rising awareness of minimally invasive treatment options, and improving access to advanced medical technologies. Healthcare modernization across emerging economies is enabling broader adoption of interventional procedures, while increasing demand for effective vascular disease management is creating opportunities for drug-coated balloon technologies. Growing investments in hospitals and specialist treatment capabilities are also supporting the expansion of advanced catheter-based interventions throughout the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Evidence AdoptionGermany emphasizes clinically validated drug-coated balloon catheter technologies supported by strong hospital purchasing standards. Healthcare providers prioritize devices with proven procedural performance and long-term effectiveness for vascular interventions.
France 🇫🇷
Hospital Treatment OptimizationFrance focuses on optimizing vascular care through selective adoption of drug-coated balloon catheter technologies in hospital settings. Physicians increasingly evaluate devices that support effective restenosis management while aligning with clinical practice standards.
Italy 🇮🇹
Vascular Care ExpansionItaly continues to strengthen the drug-coated balloon catheter market through expanding interventional cardiology and peripheral vascular services. Healthcare providers prioritize dependable device performance and treatment approaches that reduce the need for repeat interventions.
Japan 🇯🇵
Precision Device UtilizationJapan encourages adoption of drug-coated balloon catheters through precision-focused interventional practices and advanced cardiovascular care. Medical institutions value product reliability, procedural efficiency, and compatibility with established treatment protocols.
South Korea 🇰🇷
Innovation-Driven ProceduresSouth Korea integrates drug-coated balloon catheters into modern vascular treatment strategies supported by technologically advanced hospitals. Demand reflects interest in minimally invasive procedures and continuous adoption of next-generation interventional devices.
United States 🇺🇸
Advanced Interventional CareThe U.S. drug-coated balloon catheter market benefits from broad adoption of minimally invasive vascular procedures across specialized healthcare centers. Clinical focus remains on improving treatment outcomes while expanding the use of advanced catheter technologies in peripheral interventions.
Segment Leadership and Growth Trends
Drug-coated Balloon Catheter Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Paclitaxel (Largest Segment) vs Sirolimus (Fastest-Growing Segment)
The paclitaxel segment dominated the drug-coated balloon catheter market in 2026 with a 91.21% share, reflecting its established use in drug-coated balloon technologies for inhibiting abnormal tissue proliferation following vascular intervention. Paclitaxel-coated devices have been widely incorporated into interventional procedures because the drug can be delivered directly to the vessel wall during balloon inflation, supporting restenosis management while avoiding permanent implantation. Its established clinical utilization and familiarity among interventional practitioners continue to underpin the segment's leading position.
Sirolimus is expected to be the fastest-growing drug segment as interest increases in alternative drug-coated balloon technologies with favorable therapeutic characteristics. Sirolimus is widely recognized for its antiproliferative properties and is gaining attention as device developers and clinicians seek additional options for localized drug delivery during vascular interventions. Continued innovation in balloon catheter design, growing emphasis on minimally invasive treatment, and demand for technologies that can address restenosis without leaving a permanent implant are supporting the segment's expansion.
Product Segment Analysis: Peripheral Vascular Disease (Largest & Fastest-Growing Segment)
Peripheral vascular disease represented the largest share of the drug-coated balloon catheter market in 2026 at 69.73% and is also the fastest-growing product segment. Drug-coated balloon catheters are increasingly valuable in peripheral vascular interventions because they enable localized delivery of antiproliferative drugs while treating narrowed or obstructed vessels without requiring a permanent scaffold. Growing clinical attention to peripheral artery disease, increasing preference for minimally invasive revascularization, and the need for effective management of recurrent vascular narrowing are strengthening demand for these devices. Continued development of specialized balloon technologies for complex peripheral lesions is further supporting the segment's momentum.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Paclitaxel, Sirolimus | Paclitaxel | Sirolimus |
| Product | Coronary Artery Disease, Peripheral Vascular Disease | Peripheral Vascular Disease | Peripheral Vascular Disease |
| End-use | Hospital, Clinics, Ambulatory Surgical Centers | Hospital | Ambulatory Surgical Centers |
Competitive Landscape and Market Positioning
Prominent players in the drug-coated balloon catheter market:
1. Boston Scientific Corporation (United States)
2. Medtronic plc (Ireland)
3. Abbott Laboratories (United States)
4. B. Braun SE (Germany)
5. Koninklijke Philips N.V. (Netherlands)
6. MicroPort Scientific Corporation (China)
7. Lepu Medical Technology (Beijing) Co. Ltd. (China)
8. Meril Life Sciences Pvt. Ltd. (India)
9. Cordis Corporation (United States)
10. Concept Medical Inc. (India)
The drug-coated balloon catheter market is advancing through continuous innovation in minimally invasive treatment technologies. R&D investments are focused on improving drug delivery efficiency and procedural outcomes. New product introductions are enhancing clinical precision and patient recovery performance. Collaborative initiatives are also supporting faster clinical adoption and technological refinement.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation (United States) | |||||||
| Medtronic plc (Ireland) | |||||||
| Abbott Laboratories (United States) | |||||||
| B. Braun SE (Germany) | |||||||
| Koninklijke Philips N.V. (Netherlands) | |||||||
| MicroPort Scientific Corporation (China) | |||||||
| Lepu Medical Technology (Beijing) Co. Ltd. (China) | |||||||
| Meril Life Sciences Pvt. Ltd. (India) | |||||||
| Cordis Corporation (United States) | |||||||
| Concept Medical Inc. (India). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Teleflex Incorporated | Oct-25 | Teleflex Incorporated entered a definitive agreement to acquire substantially all of BIOTRONIK’s Vascular Intervention business for approximately EUR 760 million. The transaction strengthens Teleflex’s interventional portfolio, expanding its global footprint in vascular access and drug-coated balloon-adjacent technologies used in minimally invasive cardiovascular procedures. |
| BrosMed | Feb-25 | BrosMed entered a strategic collaboration with Cordis to commercialize the VaSecure next-generation drug-coated balloon in China. The partnership focuses on strengthening distribution channels, accelerating clinical adoption, and expanding patient access to advanced drug-coated balloon technologies within China’s growing interventional cardiovascular market. |
| Cordis | Oct-23 | Cordis completed the acquisition of MedAlliance, integrating SELUTION SLR sustained sirolimus drug-eluting balloon technology into its cardiovascular portfolio. The acquisition enhances Cordis’s interventional product offering and strengthens its competitive position in drug-coated balloon and drug-eluting balloon technologies for coronary and peripheral artery disease treatment. |
| Boston Scientific Corporation | Feb-22 | Boston Scientific Corporation acquired Baylis Medical Company, expanding its transseptal access and catheter-based intervention portfolio. The acquisition enhances its structural heart and vascular intervention capabilities by integrating guidewires, sheaths, and balloon dilators, strengthening its position in minimally invasive cardiovascular procedures and related delivery technologies. |
| B. Braun Interventional Systems Inc. | Mar-21 | B. Braun Interventional Systems collaborated with Infraredx, a Nipro company, to conduct clinical trials for its SeQuent Please ReX drug-coated PTCA balloon catheter. The partnership supported regulatory advancement efforts, contributing to FDA approval pathways and strengthening long-term collaboration between B. Braun and Nipro in coronary artery disease intervention technologies. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Drug-coated Balloon Catheter Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Physician Specialty | Interventional Cardiology, Vascular Surgery, Interventional Radiology |
| Procedure Volume | Low-volume Centers, Medium-volume Centers, High-volume Centers |
| Purchasing Model | Direct Hospital Procurement, Group Purchasing Organization, Distributor-mediated Procurement |
Drug-coated Balloon Catheter Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Interventional Cardiology Procedure Adoption Analysis |
|
| Hospital Procurement Decision Framework |
|
| Reimbursement and Market Access Evaluation |
|
Need a different cut of the data?
Request Custom ResearchHow much is the drug-coated balloon catheter market worth?
How is the drug-coated balloon catheter industry projected to perform over the next decade?
How is the shift toward implant-free revascularization shaping clinical adoption in the drug-coated balloon catheter market?
What is driving the expansion of minimally invasive vascular procedures in the drug-coated balloon catheter market?
Why does paclitaxel remain the leading type in the drug-coated balloon catheter market?
Which product segment is growing the fastest in the drug-coated balloon catheter market?
Why does North America lead the drug-coated balloon catheter market?
What is driving growth in the drug-coated balloon catheter market across Asia Pacific?
What are the key competitors in the drug-coated balloon catheter landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization